This article is more than 5 years old. Information may no longer be current.
Animas to cease sale of insulin pumps
Animas Corporation, a Johnson & Johnson Diabetes Care company, announced it will discontinue the manufacturing and sale of its insulin pumps and close operations, exiting the insulin pump market, according to a company press release.
Animas will partner with Medtronic to transfer its patients using the Animas Vibe and OneTouch Ping insulin pumps to a Medtronic pump.
“We are incredibly grateful to our patients and health care partners for the trust, confidence and loyalty they have placed in Animas products over the last 12 years,” Valerie Asbury, general manager of Animas, said in the release. “With changing needs of customers, rapidly evolving market dynamics and increased competitive pressures, it proved too difficult to sustain the insulin pump business, and we decided to pursue an exit of the business. This decision was extremely difficult and comes following the extensive exploration of all other viable options for the Animas business.”
About 90,000 people with diabetes are currently using Animas pumps.
Patients, caregivers and health care providers can find more information at www.medtronicdiabtes.com/Animas.